Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce the appointment of Mr Alex Snow to its Board of Directors as Deputy Chairman. He brings significant strategic development and financial experience to the board.
Exscientia, the leading Artificial Intelligence (AI)-driven drug discovery company, is delighted to announce the opening of its new offices in central Oxford, UK, in the UK’s most dynamic life science cluster.
Exscientia, the leading Artificial Intelligence (AI)-driven drug discovery company, is delighted to announce success at the 2017 Courier Awards, held in Dundee and organised by D.C. Thomson, a leading British publishing house.
Exscientia, the leading Artificial Intelligence (AI)-driven drug discovery company, is pleased to announce that it was the winner of the Best Emerging Biotech Company Award at the OBN Annual Awards ceremony
- Evotec to invest € 15 M in Exscientia, A pioneer of Artificial Intelligence (“AI”) in drug discovery
- New funds will enable Exscientia to accelerate growth
- Expansion of existing partnership to discover novel immuno-oncology therapeutics
- First Evotec project supported by recent € 75 M loan facility from the European Investment Bank
Hamburg, Germany, Dundee, UK: 28 September 2017
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and Exscientia Ltd (“Exscientia”) today announced that Evotec has made a € 15 M investment to take a minority stake in Exscientia. Through this investment, Evotec becomes the first strategic shareholder in the UK based company. Exscientia is focused on Artificial Intelligence (“AI”)-driven drug discovery and design. With more than 1800 scientists, Evotec has one of the largest and leading drug discovery platforms in the industry.
Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce it has entered into a strategic drug discovery collaboration with GlaxoSmithKline (GSK). During this collaboration, Exscientia will apply its AI enabled platform and combine this with the expertise of GSK, in order to discover novel and selective small molecules for up to 10 disease-related targets, nominated by GSK across multiple therapeutic areas.
Exscientia will receive research payments from GSK to undertake new discovery programmes with nominated targets with the goal of delivering pre-clinical candidates. In addition to research funding, Exscientia is eligible to receive near-term lead and pre-clinical candidate milestones if all objectives are achieved. The total amount payable by GSK to Exscientia on achieving these milestones is £33 million, if all 10 projects are advanced. No further financial details have been disclosed.
Exscientia社は、GSKが指定する標的タンパク質に対して、医薬品候補化合物に到達することを目的とする創薬プログラムの実施の対価として、GSKから研究資金を受領します。 研究資金提供に加えて、すべての目的が達成されるならば、Exscientia社はnear-term leadと医薬品候補化合物達成のマイルストーンを受ける資格があります。 10の全てのプロジェクトが進展して、これらのマイルストーンが達成されるとExscientia社へGSKからGBP£3300万が支払われる契約になっています。 さらなる契約金の詳細については明らかにされていません。
Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is delighted to announce that its Chief Executive Officer Andrew Hopkins has been named Chemistry World ‘Entrepreneur of the Year’. Chief Technology Officer Jérémy Besnard also won the ‘Rising Star in Industry’ Award at the Chemistry Means Business 2017 Awards, hosted by the UK Royal Society of Chemistry in Manchester this week.